The Dawn of Human Age Reversal: The 2026 Clinical Shift

Clinical trials for partial epigenetic reprogramming have officially transitioned to human subjects following FDA clearance for a gene therapy targeting optic nerve rejuvenation based on David Sinclair’s research.